METHODS OF IDENTIFYING MODULATORS OF HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED (HCN) CHANNELS

• US 20090029366A1
• Filed: 03/27/2008
• Published: 01/29/2009
• Est. Priority Date: 03/28/2007
• Status: Abandoned Application

• Current Assignee: Wyeth (Pfizer Inc.)
• Original Assignee: Wyeth (Pfizer Inc.)
• Inventors: Lu, Qiang, Bowlby, Mark, Shan, Qin, Vasylyev, Dmytro, Kaftan, Edward
• Application Number:
  US12/057,309
• Publication Number:
  US 20090029366A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: G01N 33/502 for testing non-proliferative effects
• CPC Class Codes: G01N 33/6872 Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Abstract

Methods, including high-throughput methods, for identifying modulators of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels.

Claims

1. A method for identifying a modulator of a hyperpolarization-activated cyclic nucleotide gated (HCN) channel comprising the steps of:

(a) providing a cell expressing an HCN channel in a saline solution comprising a membrane potential sensitive dye;

(b) contacting the cell with a test agent;

(c) adding a sodium/potassium diluent to the saline solution of (a) to thereby induce hyperpolarization, wherein the diluent is optionally supplemented with the membrane potential sensitive dye; and

(d) assaying attenuation or enhancement of hyperpolarization, as compared to a control level of hyperpolarization, wherein attenuation of hyperpolarization indicates that the test agent is an HCN channel antagonist, and wherein enhancement of hyperpolarization indicates that the test agent is an HCN channel agonist.

2. The method of claim 1, wherein the HCN channel comprises alpha subunits selected from the group consisting of HCN1, HCN2, HCN3, and HCN4 alpha subunits.

3. The method of claim 1, wherein the HCN channel is a heteromeric channel.

4. The method of claim 1, wherein the HCN channel is a homomeric channel.

5. The method of claim 2, wherein the HCN channel comprises an HCN1 alpha subunit and an HCN2 alpha subunit.

6. The method of claim 2, wherein the HCN channel comprises an HCN1 alpha subunit and an HCN3 alpha subunit.

7. The method of claim 2, wherein the HCN channel comprises an HCN1 alpha subunit and an HCN4 alpha subunit.

8. The method of claim 2, wherein the HCN channel comprises an HCN2 alpha subunit and an HCN3 alpha subunit.

9. The method of claim 2, wherein the HCN channel comprises an HCN2 alpha subunit and an HCN4 alpha subunit.

10. The method of claim 2, wherein the HCN channel comprises an HCN3 alpha subunit and an HCN4 alpha subunit.

11. The method of claim 1, wherein the HCN channel comprises HCN alpha subunits and an auxiliary beta subunit.

12. The method of claim 11, wherein the auxiliary beta subunit is encoded by a member of the KCNE gene family.

13. The method of claim 11, wherein the alpha subunits and the auxiliary beta subunit are expressed from a single vector.

14. The method of claim 11, wherein the alpha subunits and the auxiliary beta subunit are expressed from different vectors.

15. The method of claim 1, wherein the cell expressing an HCN channel endogenously express an HCN channel.

16. The method of claim 15, wherein the cell expressing an HCN channel is selected from the group consisting of cardiac cells, neural cells, photoreceptor cells, and taste bud cells.

17. The method of claim 16, wherein the cardiac cells are selected from the group consisting of sino-atrial node cells, atrial muscle cells, and ventricular muscle cells.

18. The method of claim 16, wherein the neural cells are selected from the group consisting of olfactory cells, cerebral cortical cells, hippocampal cells, thalamus cells, amygdale cells, superior collicular cells, inferior collicular cells, cerebellar cells, Purkinje cells, and neural stem cells.

19. The method of claim 1 wherein the cell stably expresses the HCN channel.

20. The method of claim 1, wherein the cell transiently expresses the HCN channel.

21. The method of claim 1, wherein the cell is a eukaryotic cell.

22. The method of claim 21, wherein the eukaryotic cell is selected from the group consisting of amphibian cells, yeast cells, and mammalian cells.

23. The method of claim 22, wherein the eukaryotic cell is a mammalian cell.

24. The method of claim 23, wherein the mammalian cell is selected from the group consisting of COS cells, mouse L cells, CHO cells, human embryonic kidney cells, and African green monkey cells.

25. The method of claim 1, wherein the saline solution of step (a) comprises at least 50 mM of sodium ions and at least 5 mM of potassium ions.

26. The method of claim 1, wherein the saline solution of step (a) is selected from the group consisting of Ringer'"'"'s Lactate, Tyrode'"'"'s buffer, Kreb'"'"'s buffer, Hank'"'"'s balanced salt solution, and modified Hank'"'"'s balanced salt solution.

27. The method of claim 1 wherein the sodium/potassium diluent reduces the cation concentration of the saline solution by at least five fold.

28. The method of claim 1 wherein the sodium/potassium diluent reduces the cation concentration of the saline solution by at least ten fold.

29. The method of claim 1 wherein the sodium/potassium diluent reduces the cation concentration of the saline solution by at least twenty fold.

30. The method of claim 1 wherein the sodium/potassium diluent reduces the cation concentration of the saline solution by at least thirty fold.

31. The method of claim 1, wherein the sodium/potassium diluent reduces the cation concentration of the saline solution by at least fifty fold.

32. The method of claim 1, wherein the sodium/potassium diluent reduces the concentration of sodium ions in the saline solution to less than about 30 mM.

33. The method of claim 1, wherein the sodium/potassium diluent reduces the concentration of potassium ions in the saline solution to less than about 10 mM.

34. The method of claim 1, wherein the saline solution further comprises an impermeant cation.

35. The method of claim 34, wherein the impermeant cation is selected from the group consisting of N-methyl-D-glucamine, choline, tetraethylammonium, tetrethymethyammonium, and tetrapropylammonium.

36. The method of claim 1, wherein the sodium/potassium diluent further comprises an HCN channel impermeant cation.

37. The method of claim 36, wherein the impermeant cation is selected from the group consisting of N-methyl-D-glucamine, choline, tetraethylammonium, tetrethymethyammonium, and tetrapropylammonium.

38. The method of claim 1, wherein the membrane potential sensitive dye is selected from the group consisting of oxonols, carbocyanine, rhodamines, and derivatives thereof.

39. The method of claim 38, wherein the membrane potential sensitive dye is an oxonol derivative.

40. The method of claim 39, wherein the oxonol derivative is a 3-bis-barbituric acid oxonol derivative.

41. The method of claim 40, wherein the 3-bis-barbituric acid oxonol derivative is bis-(1,3-dibutylbarbituric acid) trimethine oxonol [DiBac₄(3)], bis-(1,3-diethylthiobarbituric acid)trimethine oxonol, bis-(1,3-dibutylbarbituric acid)pentamethine oxonol, or a combination thereof.

42. The method of claim 1, wherein the membrane potential sensitive dye is suitable for use in a fluorescent imaging plate reader system.

43. The method of claim 1, which is performed on a high-throughput scale.

44. The method of claim 1, wherein the modulator is an agent that blocks an HCN channel, an agent that inhibits an HCN channel, an agent that activates an HCN channel, or an agent that enhances HCN channel conductance.

45. The method of claim 1, wherein the test agent is selected from the group consisting of small molecules, antibodies or fragments thereof, peptides, proteins, oligopeptides polysaccharides, lipids, fatty acids, nucleic acids, and nucleic acid-protein fusions.

46. A method of selecting a cell line that expresses a hyperpolarization-activated cyclic nucleotide gated (HCN) channel comprising the steps of:

(a) providing a cell suspected to express a hyperpolarization-activated cyclic nucleotide gated (HCN) channel in a saline solution supplemented with a membrane potential sensitive dye (MPSD);

(b) adding a sodium/potassium diluent solution to the saline solution of (a) to thereby induce hyperpolarization; and

(c) selecting a cell that is hyperpolarized upon addition of the sodium/potassium diluent solution.

47. The method of claim 46, further comprising:

(d) selecting a cell that shows inhibition of induced hyperpolarization when contacted with an HCN channel inhibitor.

48. The method of claim 47, wherein the HCN channel inhibitor is CsCl, ZD7288, ORG 34167, cilobradine, ivabradine, zatebradine, capsezepine, lidocaine, or loperamide.

49. The method of claim 46, further comprising:

(d) selecting a cell that shows enhancement of induced hyperpolarization when contacted with an HCN channel activator.

50. The method of claim 49, wherein the HCN channel activator induces elevated levels of cAMP.

51. The method of claim 46, further comprising:

(d) establishing a stable cell line using the cell of step (c).

52. A cell line prepared according to the method of claim 46.